Lynn Tetrault is recorded as Board Member at Neogenomics Inc (NEO) and Board Member at Alumis Inc. (ALMS) since January 1, 2025. The newest filing on record that lists Lynn Tetrault as Board Member at Alumis Inc. (ALMS) is dated May 18, 2026. Alumis Inc. reported in an 8-K filed May 21, 2025 that Lynn Tetrault was appointed Director, effective May 21, 2025. Lynn Tetrault has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for Neogenomics Inc on May 21, 2026. Neogenomics Inc is classified in the Diagnostics & Research industry within the Healthcare sector. Alumis Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Neogenomics Inc includes Chris Smith (CEO and Board Member), Christopher Smith (CEO and Board Member), Tony Zook (CEO, Chairman and Board Member) and 7 others.
“at the recommendation of the Nominating and Corporate Governance Committee of the Board, Lynn Tetrault was appointed to the Board as of the Effective Time.”
“I'd like to welcome you to NeoGenomics first quarter 2022 conference call. Joining me to this call from our Fort Myers headquarters are Bill Bonello, our Chief Financial Officer, Doug Brown, our Chief Strategy and Corporate Development Officer, and Charlie Eidson, our Director of Investor Relations.”
“I think what I'd start off saying is, I have had the privilege of knowing Mark for 22 years and work with him for 15 years at AstraZeneca. So, I have no real experience of what he's capable of delivering.”
